• J M Diamond, D J Lederer, S M Kawut, J Lee, V N Ahya, S Bellamy, S M Palmer, V N Lama, S Bhorade, M Crespo, E Demissie, J Sonett, K Wille, J Orens, P D Shah, A Weinacker, D Weill, B A Kohl, C C Deutschman, S Arcasoy, A S Shah, J A Belperio, D Wilkes, J M Reynolds, L B Ware, J D Christie, and Lung Transplant Outcomes Group.
• Pulmonary, Allergy, and Critical Care Division, Department of Anesthesia and Critical Care, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
• Am. J. Transplant. 2011 Nov 1; 11 (11): 2517-22.

AbstractPrimary graft dysfunction (PGD) after lung transplantation may result from ischemia reperfusion injury (IRI). The innate immune response to IRI may be mediated by Toll-like receptor and IL-1-induced long pentraxin-3 (PTX3) release. We hypothesized that elevated PTX3 levels were associated with PGD. We performed a nested case control study of lung transplant recipients with idiopathic pulmonary fibrosis (IPF) or chronic obstructive pulmonary disease (COPD) from the Lung Transplant Outcomes Group cohort. PTX3 levels were measured pretransplant, and 6 and 24 h postreperfusion. Cases were subjects with grade 3 PGD within 72 h of transplantation and controls were those without grade 3 PGD. Generalized estimating equations and multivariable logistic regression were used for analysis. We selected 40 PGD cases and 79 non-PGD controls. Plasma PTX3 level was associated with PGD in IPF but not COPD recipients (p for interaction < 0.03). Among patients with IPF, PTX3 levels at 6 and 24 h were associated with PGD (OR = 1.6, p = 0.02 at 6 h; OR = 1.4, p = 0.008 at 24 h). Elevated PTX3 levels were associated with the development of PGD after lung transplantation in IPF patients. Future studies evaluating the role of innate immune activation in IPF and PGD are warranted.©2011 The Authors Journal compilation © 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

28 keywords...

hide…